Bleeding Disorders
Conference Coverage
SCD, beta-thalassemia: CRISPR-based gene therapy `transformative’
Phase 3 results suggest potential for a “functional cure”; this treatment could become first-ever approved CRISPR gene-editing therapy.
News
FDA approves first gene therapy for hemophilia A
The expensive, one-time, single-dose IV infusion for severe hemophilia A may offer patients years of freedom from infusions.
Latest News
Guide explains nonsurgical management of major hemorrhage
Bleeding affects everybody in medicine, from family doctors in smaller institutions who work in emergency departments to obstetricians and...
From the Journals
Focus of new ASH VTE guidelines: Thrombophilia testing
New guidelines recommend testing for thrombophilia in patients with VTE provoked by a nonsurgical major transient risk factor or associated with...
From the Journals
Red-cell donor’s sex does not affect transfusion survival
New study showed that the sex of a red blood cell donor has no bearing on the survival of the transfusion recipient.
Sponsored Supplement
Best Practices: In the Management of Hemophilia
From the Journals
Hemophilia A gene therapy under FDA review
Recently published clinical data showed that a costly new gene therapy for hemophilia A was found largely durable at 2 years.
From the Journals
Efanesoctocog alfa treatment: ‘Victory’ over hemophilia A
In a phase 3 study of patients with severe hemophilia A, a new factor VIII injection given weekly prevented almost all bleeding episodes.
News
Europe approves first gene therapy for hemophilia B
Exorbitantly priced gene therapy to treat hemophilia B has been approved for sale across the European Union and European Economic Area.
News
FDA approves once-weekly hemophilia A product
Newly approved by the FDA, this replacement therapy for a rare bleeding disorder has been found to reduce both dosing frequency and bleeds.
From the Journals
Abnormal bleeding common among youth with joint hypermobility
Study suggests that children with generalized joint hypermobility should be routinely screened for abnormal bleeding symptoms and referred as...
Conference Coverage
ITP: Biologic beat placebo, but few patients improved
Exorbitant efgartigimod meets primary endpoint in only 21.8% of patients with chronic disease.